{"entity":{"type":"insider","cik":"0001357396","url":"/insider/0001357396","json_url":"/insider/0001357396.json","name":"Rombotis Spiro George","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":39,"n_filings":24,"first":"2006-05-18","last":"2023-12-26","span_basis":"filed_date"},"name_variants":[{"name":"Rombotis Spiro George","source":"filing","n_filings":19,"first_seen":"2007-12-21","last_seen":"2023-12-26"},{"name":"Rombotis Spiro","source":"filing","n_filings":5,"first_seen":"2006-05-18","last_seen":"2006-09-18"}],"transactions":[{"id":7925434,"accession":"0001104659-23-129185","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-129185","line_url":"/filing/0001104659-23-129185#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6070.0,"shares_display":"6,070","price_per_share":3.315,"price_display":"3.32","price_state":"stated","total_value":20122.05,"total_display":"20,122.05","total_whole":"20,122","shares_owned_after":68658.0,"shares_owned_after_display":"68,658","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-21","filed_date":"2023-12-26","scope":"insider"},{"id":4987981,"accession":"0001104659-21-142474","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-142474","line_url":"/filing/0001104659-21-142474#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":4.5,"price_display":"4.50","price_state":"stated","total_value":18000.0,"total_display":"18,000.00","total_whole":"18,000","shares_owned_after":4988.0,"shares_owned_after_display":"4,988","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-18","filed_date":"2021-11-22","scope":"insider"},{"id":5557846,"accession":"0001104659-13-043964","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-13-043964","line_url":"/filing/0001104659-13-043964#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":300000.0,"total_display":"300,000.00","total_whole":"300,000","shares_owned_after":268292.0,"shares_owned_after_display":"268,292","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-21","filed_date":"2013-05-22","scope":"insider"},{"id":4575297,"accession":"0001104659-13-044753","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-13-044753","line_url":"/filing/0001104659-13-044753#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":300000.0,"total_display":"300,000.00","total_whole":"300,000","shares_owned_after":241416.0,"shares_owned_after_display":"241,416","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-21","filed_date":"2013-05-24","scope":"insider"},{"id":9190545,"accession":"0001104659-11-071275","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-11-071275","line_url":"/filing/0001104659-11-071275#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15902.0,"shares_display":"15,902","price_per_share":0.495,"price_display":"0.50","price_state":"stated","total_value":7871.49,"total_display":"7,871.49","total_whole":"7,871","shares_owned_after":746516.0,"shares_owned_after_display":"746,516","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-23","filed_date":"2011-12-27","scope":"insider"},{"id":9137886,"accession":"0001104659-11-053342","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-11-053342","line_url":"/filing/0001104659-11-053342#line-3","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President and C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and C.E.O.","security_title":"Preferred Convertible Exchangeable Stock 6%","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1200.0,"shares_display":"1,200","price_per_share":3.058,"price_display":"3.06","price_state":"stated","total_value":3669.6,"total_display":"3,669.60","total_whole":"3,670","shares_owned_after":1600.0,"shares_owned_after_display":"1,600","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-09-23","filed_date":"2011-09-26","scope":"insider"},{"id":9137885,"accession":"0001104659-11-053342","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-11-053342","line_url":"/filing/0001104659-11-053342#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President and C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and C.E.O.","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24100.0,"shares_display":"24,100","price_per_share":0.505,"price_display":"0.50","price_state":"stated","total_value":12170.5,"total_display":"12,170.50","total_whole":"12,171","shares_owned_after":608530.0,"shares_owned_after_display":"608,530","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-09-23","filed_date":"2011-09-26","scope":"insider"},{"id":9137884,"accession":"0001104659-11-053342","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-11-053342","line_url":"/filing/0001104659-11-053342#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President and C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and C.E.O.","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":0.593,"price_display":"0.59","price_state":"stated","total_value":2965.0,"total_display":"2,965.00","total_whole":"2,965","shares_owned_after":584430.0,"shares_owned_after_display":"584,430","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-09-22","filed_date":"2011-09-26","scope":"insider"},{"id":9085739,"accession":"0001209191-11-047905","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-11-047905","line_url":"/filing/0001209191-11-047905#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Preferred Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400.0,"shares_display":"400","price_per_share":3.227,"price_display":"3.23","price_state":"stated","total_value":1290.8,"total_display":"1,290.80","total_whole":"1,291","shares_owned_after":400.0,"shares_owned_after_display":"400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-09-13","filed_date":"2011-09-14","scope":"insider"},{"id":9085738,"accession":"0001209191-11-047905","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-047905","line_url":"/filing/0001209191-11-047905#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12000.0,"shares_display":"12,000","price_per_share":0.671,"price_display":"0.67","price_state":"stated","total_value":8052.0,"total_display":"8,052.00","total_whole":"8,052","shares_owned_after":579430.0,"shares_owned_after_display":"579,430","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-09-13","filed_date":"2011-09-14","scope":"insider"},{"id":8969093,"accession":"0001209191-11-045496","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-045496","line_url":"/filing/0001209191-11-045496#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9232.0,"shares_display":"9,232","price_per_share":0.728,"price_display":"0.73","price_state":"stated","total_value":6720.896,"total_display":"6,720.90","total_whole":"6,721","shares_owned_after":567430.0,"shares_owned_after_display":"567,430","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-08-22","filed_date":"2011-08-24","scope":"insider"},{"id":7670032,"accession":"0001209191-10-023882","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-023882","line_url":"/filing/0001209191-10-023882#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, $0.001 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8350.0,"shares_display":"8,350","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":20875.0,"total_display":"20,875.00","total_whole":"20,875","shares_owned_after":483198.0,"shares_owned_after_display":"483,198","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-04-23","filed_date":"2010-04-27","scope":"insider"},{"id":3685586,"accession":"0001209191-08-064070","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-08-064070","line_url":"/filing/0001209191-08-064070#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":0.37,"price_display":"0.37","price_state":"stated","total_value":1110.0,"total_display":"1,110.00","total_whole":"1,110","shares_owned_after":441548.0,"shares_owned_after_display":"441,548","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-12-02","filed_date":"2008-12-04","scope":"insider"},{"id":3863128,"accession":"0001209191-08-062257","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-08-062257","line_url":"/filing/0001209191-08-062257#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":900.0,"shares_display":"900","price_per_share":0.311,"price_display":"0.31","price_state":"stated","total_value":279.9,"total_display":"279.90","total_whole":"280","shares_owned_after":438548.0,"shares_owned_after_display":"438,548","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-11-20","filed_date":"2008-11-21","scope":"insider"},{"id":3863126,"accession":"0001209191-08-062257","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-08-062257","line_url":"/filing/0001209191-08-062257#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8000.0,"shares_display":"8,000","price_per_share":0.355,"price_display":"0.36","price_state":"stated","total_value":2840.0,"total_display":"2,840.00","total_whole":"2,840","shares_owned_after":437648.0,"shares_owned_after_display":"437,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-11-19","filed_date":"2008-11-21","scope":"insider"},{"id":9266039,"accession":"0001209191-08-061680","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-08-061680","line_url":"/filing/0001209191-08-061680#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17000.0,"shares_display":"17,000","price_per_share":0.466,"price_display":"0.47","price_state":"stated","total_value":7922.0,"total_display":"7,922.00","total_whole":"7,922","shares_owned_after":429648.0,"shares_owned_after_display":"429,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-11-18","filed_date":"2008-11-19","scope":"insider"},{"id":3661570,"accession":"0001209191-08-061559","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-08-061559","line_url":"/filing/0001209191-08-061559#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17000.0,"shares_display":"17,000","price_per_share":0.466,"price_display":"0.47","price_state":"stated","total_value":7922.0,"total_display":"7,922.00","total_whole":"7,922","shares_owned_after":429648.0,"shares_owned_after_display":"429,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-11-18","filed_date":"2008-11-19","scope":"insider"},{"id":9266038,"accession":"0001209191-08-061680","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-08-061680","line_url":"/filing/0001209191-08-061680#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":0.5,"price_display":"0.50","price_state":"stated","total_value":1000.0,"total_display":"1,000.00","total_whole":"1,000","shares_owned_after":412648.0,"shares_owned_after_display":"412,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-11-17","filed_date":"2008-11-19","scope":"insider"},{"id":3661569,"accession":"0001209191-08-061559","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-08-061559","line_url":"/filing/0001209191-08-061559#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":0.5,"price_display":"0.50","price_state":"stated","total_value":1000.0,"total_display":"1,000.00","total_whole":"1,000","shares_owned_after":412648.0,"shares_owned_after_display":"412,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-11-17","filed_date":"2008-11-19","scope":"insider"},{"id":2633114,"accession":"0001209191-08-048292","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-08-048292","line_url":"/filing/0001209191-08-048292#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8900.0,"shares_display":"8,900","price_per_share":1.71,"price_display":"1.71","price_state":"stated","total_value":15219.0,"total_display":"15,219.00","total_whole":"15,219","shares_owned_after":410648.0,"shares_owned_after_display":"410,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-08-19","filed_date":"2008-08-19","scope":"insider"},{"id":2633105,"accession":"0001209191-08-048292","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-08-048292","line_url":"/filing/0001209191-08-048292#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":1.76,"price_display":"1.76","price_state":"stated","total_value":176.0,"total_display":"176.00","total_whole":"176","shares_owned_after":401748.0,"shares_owned_after_display":"401,748","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-08-18","filed_date":"2008-08-19","scope":"insider"},{"id":3900321,"accession":"0001005477-08-004000","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-08-004000","line_url":"/filing/0001005477-08-004000#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.018,"price_display":"2.02","price_state":"stated","total_value":10090.0,"total_display":"10,090.00","total_whole":"10,090","shares_owned_after":401648.0,"shares_owned_after_display":"401,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-06-05","filed_date":"2008-06-05","scope":"insider"},{"id":3900320,"accession":"0001005477-08-004000","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-08-004000","line_url":"/filing/0001005477-08-004000#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.036,"price_display":"2.04","price_state":"stated","total_value":10180.0,"total_display":"10,180.00","total_whole":"10,180","shares_owned_after":396648.0,"shares_owned_after_display":"396,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-06-04","filed_date":"2008-06-05","scope":"insider"},{"id":4008778,"accession":"0001005477-08-003561","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-08-003561","line_url":"/filing/0001005477-08-003561#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":2.298,"price_display":"2.30","price_state":"stated","total_value":17235.0,"total_display":"17,235.00","total_whole":"17,235","shares_owned_after":391648.0,"shares_owned_after_display":"391,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-05-21","filed_date":"2008-05-21","scope":"insider"},{"id":4008776,"accession":"0001005477-08-003561","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-08-003561","line_url":"/filing/0001005477-08-003561#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.351,"price_display":"2.35","price_state":"stated","total_value":11755.0,"total_display":"11,755.00","total_whole":"11,755","shares_owned_after":384648.0,"shares_owned_after_display":"384,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-05-20","filed_date":"2008-05-21","scope":"insider"},{"id":3562918,"accession":"0001005477-08-003420","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-08-003420","line_url":"/filing/0001005477-08-003420#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.486,"price_display":"2.49","price_state":"stated","total_value":12430.0,"total_display":"12,430.00","total_whole":"12,430","shares_owned_after":379648.0,"shares_owned_after_display":"379,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-05-15","filed_date":"2008-05-16","scope":"insider"},{"id":3562916,"accession":"0001005477-08-003420","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-08-003420","line_url":"/filing/0001005477-08-003420#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":2.635,"price_display":"2.64","price_state":"stated","total_value":26350.0,"total_display":"26,350.00","total_whole":"26,350","shares_owned_after":374648.0,"shares_owned_after_display":"374,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-05-14","filed_date":"2008-05-16","scope":"insider"},{"id":2653395,"accession":"0001005477-08-002469","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-08-002469","line_url":"/filing/0001005477-08-002469#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2600.0,"shares_display":"2,600","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":7150.0,"total_display":"7,150.00","total_whole":"7,150","shares_owned_after":364648.0,"shares_owned_after_display":"364,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-03-20","filed_date":"2008-03-21","scope":"insider"},{"id":2653255,"accession":"0001005477-08-002469","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-08-002469","line_url":"/filing/0001005477-08-002469#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3200.0,"shares_display":"3,200","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":8800.0,"total_display":"8,800.00","total_whole":"8,800","shares_owned_after":362048.0,"shares_owned_after_display":"362,048","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-03-19","filed_date":"2008-03-21","scope":"insider"},{"id":7885221,"accession":"0001005477-07-010405","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-07-010405","line_url":"/filing/0001005477-07-010405#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":5.47,"price_display":"5.47","price_state":"stated","total_value":5470.0,"total_display":"5,470.00","total_whole":"5,470","shares_owned_after":358848.0,"shares_owned_after_display":"358,848","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-20","filed_date":"2007-12-21","scope":"insider"},{"id":7885218,"accession":"0001005477-07-010405","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-07-010405","line_url":"/filing/0001005477-07-010405#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro George","owner_display_name":"Rombotis Spiro George","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1400.0,"shares_display":"1,400","price_per_share":5.48,"price_display":"5.48","price_state":"stated","total_value":7672.0,"total_display":"7,672.00","total_whole":"7,672","shares_owned_after":357848.0,"shares_owned_after_display":"357,848","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-19","filed_date":"2007-12-21","scope":"insider"},{"id":3960661,"accession":"0001005477-06-004708","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-06-004708","line_url":"/filing/0001005477-06-004708#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro","owner_display_name":"Rombotis Spiro","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1300.0,"shares_display":"1,300","price_per_share":5.56,"price_display":"5.56","price_state":"stated","total_value":7228.0,"total_display":"7,228.00","total_whole":"7,228","shares_owned_after":356448.0,"shares_owned_after_display":"356,448","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-15","filed_date":"2006-09-18","scope":"insider"},{"id":3960660,"accession":"0001005477-06-004708","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-06-004708","line_url":"/filing/0001005477-06-004708#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro","owner_display_name":"Rombotis Spiro","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":6.1,"price_display":"6.10","price_state":"stated","total_value":610.0,"total_display":"610.00","total_whole":"610","shares_owned_after":355148.0,"shares_owned_after_display":"355,148","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-14","filed_date":"2006-09-18","scope":"insider"},{"id":4005234,"accession":"0001005477-06-004630","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-06-004630","line_url":"/filing/0001005477-06-004630#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro","owner_display_name":"Rombotis Spiro","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":5.95,"price_display":"5.95","price_state":"stated","total_value":595.0,"total_display":"595.00","total_whole":"595","shares_owned_after":355048.0,"shares_owned_after_display":"355,048","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-12","filed_date":"2006-09-13","scope":"insider"},{"id":5228786,"accession":"0001005477-06-004608","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-06-004608","line_url":"/filing/0001005477-06-004608#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro","owner_display_name":"Rombotis Spiro","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":5.8,"price_display":"5.80","price_state":"stated","total_value":580.0,"total_display":"580.00","total_whole":"580","shares_owned_after":354948.0,"shares_owned_after_display":"354,948","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-11","filed_date":"2006-09-12","scope":"insider"},{"id":5228781,"accession":"0001005477-06-004608","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-06-004608","line_url":"/filing/0001005477-06-004608#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro","owner_display_name":"Rombotis Spiro","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":5.69,"price_display":"5.69","price_state":"stated","total_value":1707.0,"total_display":"1,707.00","total_whole":"1,707","shares_owned_after":354848.0,"shares_owned_after_display":"354,848","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-08","filed_date":"2006-09-12","scope":"insider"},{"id":3360295,"accession":"0001005477-06-004564","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-06-004564","line_url":"/filing/0001005477-06-004564#line-2","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro","owner_display_name":"Rombotis Spiro","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":4.43,"price_display":"4.43","price_state":"stated","total_value":1329.0,"total_display":"1,329.00","total_whole":"1,329","shares_owned_after":354548.0,"shares_owned_after_display":"354,548","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-07","filed_date":"2006-09-08","scope":"insider"},{"id":3360288,"accession":"0001005477-06-004564","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-06-004564","line_url":"/filing/0001005477-06-004564#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro","owner_display_name":"Rombotis Spiro","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":4.9,"price_display":"4.90","price_state":"stated","total_value":1470.0,"total_display":"1,470.00","total_whole":"1,470","shares_owned_after":354248.0,"shares_owned_after_display":"354,248","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-06","filed_date":"2006-09-08","scope":"insider"},{"id":3840189,"accession":"0001005477-06-002718","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-06-002718","line_url":"/filing/0001005477-06-002718#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357396","owner_name":"Rombotis Spiro","owner_display_name":"Rombotis Spiro","owner_url":"/insider/0001357396","role":"Director, Officer (President & C.E.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & C.E.O.","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":7.74,"price_display":"7.74","price_state":"stated","total_value":774.0,"total_display":"774.00","total_whole":"774","shares_owned_after":353948.0,"shares_owned_after_display":"353,948","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-04-17","filed_date":"2006-05-18","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":39,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":38,"open_market":true},{"code":"S","label":"Open-market sale","n":1,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":39},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001130166","name":"Cyclacel Pharmaceuticals, Inc.","url":"/issuer/0001130166","role":"Director, Officer (President and CEO)","n_filings":24,"first_seen":"2006-05-18","last_seen":"2023-12-26"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001357396","retrieved_at":"2026-08-22T05:04:24+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}